Recruiting Myasthenia Gravis Studies in Chicago
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC t...
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (...
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106....
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: ...
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis...
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG....
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized my...
About Myasthenia Gravis Clinical Trials in Chicago
Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.
There are currently 7 myasthenia gravis clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 368 participants. Research is being sponsored by Novartis Pharmaceuticals, argenx, COUR Pharmaceutical Development Company, Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myasthenia Gravis Clinical Trials in Chicago — FAQ
Are there myasthenia gravis clinical trials in Chicago?
Yes, there are 7 myasthenia gravis clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chicago?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.
Are clinical trials in Chicago free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.
What myasthenia gravis treatments are being tested?
The 7 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.
Data updated March 2, 2026 from ClinicalTrials.gov